Thyroid molecular genomic testing
Active Awarded Last action
- Contract number
- 36C25726N0108
- Awardee
-
Veracyte, Inc. UEI JS7GBP6LCMN6
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $716,112
Award facts
- Contract value 39% obligated
-
- $716,112.00 Current, with exercised options
- $1,849,956.00 Potential, with all options
- Completion date 31% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Temple, TX 76504, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 17, awarded a delivery order to Veracyte, Inc. on January 1, 2026, for thyroid molecular genomic testing services with a ceiling value of $1.85M and an ultimate completion date of July 31, 2028. This non-set-aside contract is issued under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) and will be performed in Temple, Texas. Veracyte, a South San Francisco-based medical diagnostic company, specializes in advanced genomic testing services for precision medicine, leveraging proprietary technologies and gene expression analysis to support clinical decision-making for complex medical conditions.
The delivery order represents a continuation of Veracyte's established relationship with the VA healthcare system, which has awarded the company multiple contracts for genomic classifier testing across various Veterans Integrated Service Networks. Under this firm fixed-price arrangement, Veracyte will deliver molecular diagnostic testing specifically focused on thyroid nodule assessment, enabling VA clinicians to evaluate malignancy risk and determine appropriate treatment strategies for veterans. This contract aligns with the VA's broader precision medicine initiatives and complements Veracyte's existing portfolio of federal healthcare contracts, which includes prostate cancer genomic testing and reference laboratory services across multiple VISN locations.
Quick answers
Who was awarded contract 36C25726N0108?
36C25726N0108 was awarded to Veracyte, Inc. by Veterans Integrated Service Network 17 (Veterans Health Administration) on January 1, 2026.
How much is contract 36C25726N0108 worth?
The government has obligated $716,112 on 36C25726N0108. Its potential value, with all options, is $1,849,956.
Is contract 36C25726N0108 an order under another contract?
Yes. 36C25726N0108 is a delivery order under 36F79718D0524, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract 36C25726N0108 competed?
The extent of competition for 36C25726N0108 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award